Opinion|Videos|January 31, 2025

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.


Latest CME